Loss or lower level of CEACAM1 expression has been detected in colon (16), prostate (17), and breast cancers (18), whereas high expression levels have been found in adenocarcinomas (19), non-small lung cancers (20), and melanoma (21). Here, CEACAM1 is linked to melanoma.